Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2015, Vol. 35 Issue (1): 111-119    DOI: 10.13523/j.cb.20150116
    
Market Status and Development Trend of Biotech Drugs
MAO Kai-yun, YANG Lu, WANG Heng-zhe, CHEN Da-ming
Shanghai Information Center for Life Sciences, Chinese Academy of Sciences, Shanghai 200031, China
Download: HTML   PDF(1271KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  

Thanks to the advantage of the characteristics of biotech drugs itself, biotech drugs is developing quickly. In the broader market, sales from biotechnology products are expected to account for 27% of the world's pharmaceutical sales by 2020, versus the current share of 22% in 2013. Roche is expected to remain the biggest player in the biotechnology space with sales increasing by $14.5bn to $43.5bn in 2020, representing an annual growth of 6% per annum. In support of the government, China have formed industrial clusters based on the Chinese medicine group as the leading. While total market of Chinese biotechnology drugs accounted for the global market is only 2%, but future is larger. At present China has formed industrial clusters,the biggest player of which is Sinopharm. With the increased demand for disease treatment, Biotech drugs has huge developing potential, the market will further expand.



Key wordsBiotech drugs      Market status      Monoclonal antibodies     
Received: 18 November 2014      Published: 25 January 2015
ZTFLH:  Q819  
Cite this article:

MAO Kai-yun, YANG Lu, WANG Heng-zhe, CHEN Da-ming. Market Status and Development Trend of Biotech Drugs. China Biotechnology, 2015, 35(1): 111-119.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20150116     OR     https://manu60.magtech.com.cn/biotech/Y2015/V35/I1/111


[1] EvaluatePharma. World Preview 2014, Outlook to 2020.
[2014-11-5]. http://www.evaluategroup.com/public/Reports/EvaluatePharma-World-Preview-2014.aspx.

[2] 波士顿咨询公司.在中国打造世界领先的创新型生物技术药物产业.
[2014-11-10]. http://www.bcg.com.cn/cn/newsandpublications/publications/reports/report20130130001.html.

[1] Jing-wen XU,Xue-mei ZHANG,Zhong-xiang WU,Wen-bing ZHU,Xi JIANG,Wei GONG,Li-wei YAN,Jie SONG,Hui LI,Shao-zhong DONG. Preparation and Identification of Monoclonal Antibodies Against Tree Shrews CD3ε[J]. China Biotechnology, 2018, 38(4): 54-62.
[2] LI Min, WU Ri-wei. The Market Overview of Monoclonal Antibodies in Both Domestic and Abroad[J]. China Biotechnology, 2017, 37(3): 106-114.
[3] MENG Guo-ji, DENG Yi-xi, LI Le, LUO Hao-hui, YU Yu-gen. Promotion in ProteinA Chromatography of WLB303 Monoclonal Antibody by Using Dual Flowrate to Load Sample[J]. China Biotechnology, 2016, 36(6): 65-75.
[4] LI Pu, SHI Jing, CHENG Fen, LIANG Qin-dong, KUANG Wen-bin, WANG Qin, DONG Jin-yu, TU Zhi-guang. Preparation, Characterization and Application of Monoclonal Antibodies Against Human Y box-binding Protein 1[J]. China Biotechnology, 2012, 32(6): 13-19.
[5] YANG Ya-qiong, LI Zong-hai. Recent Development of Molecular Targeted Cancer Drugs Targeted EGFR[J]. China Biotechnology, 2012, 32(05): 91-96.
[6] . Prokaryotic Expression,Purification and Preparation of Monoclonal Antibodies of Cold Inducible RNA-binding Protein in BALB/C Mice[J]. China Biotechnology, 2010, 30(03): 33-39.